On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
In PALACE™ 1
38% ACR20 response with Otezla 30 mg
twice daily (n = 168)
vs 19% with placebo (n = 168) at week 16
(primary endpoint; P = 0.0001)
In ESTEEM® 1
33% PASI-75 response with Otezla 30 mg
twice daily (n = 562)
vs 5% with placebo (n = 282) at week 16
(primary endpoint; P < 0.0001)
In RELIEF™, reduced pain and number of oral ulcers were seen with Otezla 30 mg twice daily (n = 104) vs placebo (n = 103) at week 12.
In RELIEF, the endpoints were:
Safety profile: The most common adverse reactions (≥10%) were diarrhea, nausea, headache, and upper respiratory tract infection.1
Otezla® (apremitast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Warnings and Precautions
Use in Specific Populations